Knight Therapeutics announces Health Canada has approved Nerlynx for early-stage breast cancer

Knight Therapeutics

16 July 2019 - Knight Therapeutics announced today that Health Canada has approved Nerlynx (neratinib) for the extended adjuvant treatment of women with early-stage hormone receptor positive, HER2-overexpressed/amplified breast cancer within one year after completion of trastuzumab-based adjuvant therapy.

Knight has the exclusive right to commercialise Nerlynx in Canada under a license agreement with Puma Biotechnology.

Read Knight Therapeutics press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , Canada